alexa Challenges in Administration of Corticosteroids for the
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Research Article

Challenges in Administration of Corticosteroids for the Treatment of Addison’s Disease: A Case Study of Fludrocortisone Acetate

Najim A AL-Awwadi*

College of Pharmacy, Thi Qar University, Iraq

*Corresponding Author:
Najim A AL-Awwadi
Department of Pharmacology, Faculty of Nursing
Thi Qar university, Alnasiryia, Iraq
Tel: 00964 7810877994
E-mail: [email protected]

Received date: May 23, 2017; Accepted date: June 21, 2017; Published date: June 28, 2017

Citation: AL-Awwadi NA (2017) Challenges in Administration of Corticosteroids for the Treatment of Addison’s Disease: A Case Study of Fludrocortisone Acetate. J Bioanal Biomed 9:164-168. doi: 10.4172/1948-593X.1000172

Copyright: © 2017 AL-Awwadi NA. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

 

Abstract

Fludrocortisone is a known corticosteroid used to control the amount of sodium and fluids in body. Fludrocortisone act by decreasing the amount of sodium that is excreted in your urine. It is indicated to take orally and it is recommended not to stop Fludrocortisone treatment without Physician consent as sudden stoppage leads to several moderate to severe adverse effects.

There are several moderate to severe adverse effects reported with treatment of Fludrocortisone including high Blood Pressure (BP), Heart failure, weakness of muscles, changes in mood and low immune system function. Considering this there is need to develop sustained release formulation as microparticles which help to improve patient compliance by reducing dosage frequency which overall help to reduce side effects reported with Fludrocortisone.

The aim of this research is to develop different formulations of Fludrocortisone (FLU) by using various polymers (poly(ε-caprolactone, PLC), Eudragit® RS and Eudragit® RL) and different processes (oil-in-water (O/W) solvent evaporation methods and suspension-in-oil-in-water (S/O/W) evaporation methods). Small poly(ε-caprolactone (PCL)-based microparticles have successfully developed during study which was leading to good efficiency when it was prepared by oil-in-water (O/W) emulsion method with 7.5 mg/ml of FLU.

Keywords

Share This Page

Additional Info

Loading
Loading Please wait..
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

 
© 2008-2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords